UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

May 6, 2021

Date of Report (Date of earliest event reported)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Delaware

(Exact Name of Registrant as Specified in Charter) 001-15943

06-1397316

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

251 Ballardvale Street Wilmington, Massachusetts 01887 (Address of Principal Executive Offices) (Zip Code)

meipai Ziiceauve Oilices) (Zip Gode)

781-222-6000

(Registrant's Telephone Number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

	Title of each class	rrading Symbol(s)	Name of each exchange on which registered		
	Common stock, \$0.01 par value	CRL	New York Stock Exchange		
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:					
	Written communications pursuant to Rule 425 under th	e Securities Act (17 CFR 230.425)		
	Soliciting material pursuant to Rule 14a-12 under the	Exchange Act (17 CFR 240.14a-1	2)		
	Pre-commencement communications pursuant to Rule	14d-2(b) under the Exchange Act	(17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rule	13e-4(c) under the Exchange Act	(17 CFR 240.13e-4(c))		
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).					
	Emerging growth company \Box				
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box					

Item 5.07 Submission of Matters to a Vote of Security Holders

The Company held its Annual Meeting of Shareholders on May 6, 2021. For more information on the following proposals, see the Company's proxy statement dated March 26, 2021. At the Company's Annual Meeting, the following proposals were adopted by the votes specified below:

(a)The following eleven (11) directors were elected to serve until our 2022 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below:

	Number of Shares Voted For	Number of Shares Voted Against	Number of Shares Abstained	Broker Non-Votes
James C. Foster	42,777,768	1,906,594	58,981	1,913,305
Nancy C. Andrews	44,426,451	295,223	21,669	1,913,305
Robert J. Bertolini	44,250,138	466,052	27,153	1,913,305
Deborah T. Kochevar	42,994,657	1,726,745	21,941	1,913,305
George Llado, Sr.	43,846,568	869,105	27,670	1,913,305
Martin W. MacKay	43,938,162	777,963	27,218	1,913,305
George E. Massaro	43,680,368	1,037,772	25,203	1,913,305
George M. Milne, Jr.	43,081,612	1,634,550	27,181	1,913,305
C. Richard Reese	42,923,528	1,794,732	25,083	1,913,305
Richard F. Wallman	43,532,288	1,185,887	25,168	1,913,305
Virginia M. Wilson	44,425,871	295,534	21,938	1,913,305

(b) The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers.

For	Against	Abstain	Broker Non-Votes
38,268,849	6,446,976	27,518	1,913,305

(c)The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2021.

For	Against	Abstain	Broker Non-Votes
45,171,184	1,458,386	27,078	0

Computershare Trust Company, N.A., our transfer agent, acted as independent proxy tabulator and Inspector of Election at the Annual Meeting of Shareholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Date: May 10, 2021 By: /s/ Matthew L. Daniel

Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Legal Compliance Officer and Corporate Secretary